<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="150">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563665</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-HCKD/001/SOFO/2015</org_study_id>
    <nct_id>NCT02563665</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy</brief_title>
  <official_title>A Prospective Study on Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients with chronic kidney disease (stages 3, 4 and 5) and chronic dialysis patients
      with HCV infection attending nephrology and Hepatology OPD or getting outpatient dialysis at
      the dialysis unit of ILBS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Sustained Virologic Response 24 defined as HCV RNA &lt;Lower Level of Qunatification 24 weeks after discontinuation of therapy.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of adverse Events in both groups</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>CKD With Hepatitis C</condition>
  <arm_group>
    <arm_group_label>advanced chronic kidney disease</arm_group_label>
    <description>Subjects on dialysis with GFR (Glomerular Filtration Rate) &gt; 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal replacement therapy.</arm_group_label>
    <description>Subjects who are not on dialysis with GFR (Glomerular Filtration Rate) &lt; 15</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with chronic kidney disease (stages 3, 4 and 5) and chronic dialysis patients
        with Hepatitis C infection attending nephrology and Hepatology OPD (Out Patient
        Department) or getting outpatient dialysis at the dialysis unit of Institute of Liver and
        Biliary Sciences.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with moderate to severe renal dysfunction (CKD stage 3, 4, 5) and chronic
             dialysis patients

          2. Patients consented for the study protocol by signing the informed consent.

        Exclusion Criteria:

          1. Age less than 18 years

          2. Confirmed pregnancy

          3. HCV-HIV Co infection

          4. HBV-HCV co infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Suman Lata Nayak, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Suman Lata Nayak, DM</last_name>
    <phone>011-46300000</phone>
    <email>sumanmassu2000@yahoo.co.in</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of liver and Biliary Sciences</name>
      <address>
        <city>New Dlehi</city>
        <state>Delahi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Suman Lata Nayak, DM</last_name>
      <phone>01146300000</phone>
      <email>sumanmassu2000@yahoo.co.in</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>October 7, 2015</lastchanged_date>
  <firstreceived_date>September 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
